<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606056</url>
  </required_header>
  <id_info>
    <org_study_id>202005-00046</org_study_id>
    <nct_id>NCT04606056</nct_id>
  </id_info>
  <brief_title>Risk of Acute Kidney Injury After Intravenous Contrast Computed Tomography Scans</brief_title>
  <official_title>A Single Center Observational Study- Incidence and Risk Factors of Acute Kidney Injury After Intravenous Contrast Enhanced Computed Tomography Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous iodinated contrast media is commonly used to enhance diagnostic yield of computer&#xD;
      tomography (CT) scans in clinical medicine. However, the perceived risk of contrast-induced&#xD;
      nephropathy (CIN) frequently limits its use. While CIN is often self-limiting, it can cause&#xD;
      significant morbidity by prolonging admissions and rendering an at-risk individual dialysis&#xD;
      dependent. CIN has long been observed and described in clinical studies. There is ample data&#xD;
      on CIN after administration of intraarterial contrast, but evidence is less compelling when&#xD;
      it comes to intravenous contrast. Increasing studies have called into question the actual&#xD;
      risk of intravenous contrast media. Expert panels are suggesting that the risk could have&#xD;
      been overstated, leading to contrast being withheld when indicated. There is paucity of local&#xD;
      data on this particular issue. More real world data on the actual incidence and risk factors&#xD;
      of AKI will be helpful to clinicians.&#xD;
&#xD;
      The investigators plan to conduct a single center, retrospective study, to determine the&#xD;
      incidence and risk factors of post contrast AKI in contrast enhanced CT scans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, retrospective study will be conducted, looking into all patients who had&#xD;
      contrast-enhanced CT scans done in a specified time period. Serum creatinine at baseline and&#xD;
      at 48-72 hours post-contrast of the participants will be compared to determine presence of&#xD;
      post contrast AKI (PC-AKI). Data on the participants' demographics, comorbidities, laboratory&#xD;
      results and use of nephrotoxins will also be captured and analysed.&#xD;
&#xD;
      The primary objective of this study is to determine the incidence of AKI after intravenous&#xD;
      contrast administration for contrast enhanced CT scans (CECT). The secondary objective is to&#xD;
      identify risk factors of PC-AKI and possibly come up with a risk stratification system that&#xD;
      can be utilized in clinical practice. The investigators hypothesize that there is significant&#xD;
      risk of acute kidney injury after intravenous contrast media administration, but it lower&#xD;
      than that in the setting of intraarterial contrast; and that risk factors of AKI may include:&#xD;
      pre existing chronic kidney disease, diabetes, hypertension, proteinuria, use of&#xD;
      nephrotoxins, age, increased dose of contrast.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute kidney injury</measure>
    <time_frame>31 May 2020 to 30 June 2020</time_frame>
    <description>within 1 week after contrast exposure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>Patients who underwent contrast enhanced CT scans</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient of an acute care hospital with clinical indications for contrast enchanced CT&#xD;
        scans, meeting inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Underwent one or more CT scan in CGH in the stipulated study period&#xD;
&#xD;
          2. CT scan done as an inpatient or outpatient of CGH&#xD;
&#xD;
          3. Serum creatinine available less than 6 months before scan&#xD;
&#xD;
          4. Serum creatinine available within 1 week after scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age 12 or below&#xD;
&#xD;
          2. Dialysis dependent before scan (dialysis related charge code applied 24 months before&#xD;
             scan)&#xD;
&#xD;
          3. Baseline serum creatinine not available&#xD;
&#xD;
          4. Post scan serum creatinine not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang Yin Chionh, FASN</last_name>
    <role>Study Chair</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang Yin Chionh, FASN</last_name>
    <phone>(+65)67888833</phone>
    <email>kidneyinjury@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Yin Chionh, FASN</last_name>
      <phone>(+65)6788 8833</phone>
      <email>kidneyinjury@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology. 2013 Apr;267(1):94-105. doi: 10.1148/radiol.12121394. Epub 2013 Jan 29.</citation>
    <PMID>23360737</PMID>
  </reference>
  <reference>
    <citation>McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology. 2014 Apr;271(1):65-73. doi: 10.1148/radiol.13130775. Epub 2014 Jan 16.</citation>
    <PMID>24475854</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 Oct 6;44(7):1393-9.</citation>
    <PMID>15464318</PMID>
  </reference>
  <reference>
    <citation>Leow KS, Wu YW, Tan CH. Renal-related adverse effects of intravenous contrast media in computed tomography. Singapore Med J. 2015 Apr;56(4):186-93. Review.</citation>
    <PMID>25917468</PMID>
  </reference>
  <reference>
    <citation>Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology. 2013 Sep;268(3):719-28. doi: 10.1148/radiol.13122276. Epub 2013 Apr 11.</citation>
    <PMID>23579046</PMID>
  </reference>
  <reference>
    <citation>Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Med. 2020 Jan 22;2(1):85-93. doi: 10.1016/j.xkme.2020.01.001. eCollection 2020 Jan-Feb.</citation>
    <PMID>33015613</PMID>
  </reference>
  <reference>
    <citation>Rudnick MR, Leonberg-Yoo AK, Litt HI, Cohen RM, Hilton S, Reese PP. The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk? Am J Kidney Dis. 2020 Jan;75(1):105-113. doi: 10.1053/j.ajkd.2019.05.022. Epub 2019 Aug 28. Review.</citation>
    <PMID>31473019</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 25, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravenous</keyword>
  <keyword>contrast</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>computer tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

